Last reviewed · How we verify
Mesenchymal stromal cells
Mesenchymal stromal cells (MSCs) are bone marrow-derived multipotent cells that exert immunomodulatory and tissue-regenerative effects through paracrine signaling and direct cell-cell interactions.
Mesenchymal stromal cells (MSCs) are multipotent bone marrow-derived cells that exert immunomodulatory and tissue-regenerative effects through paracrine signaling and direct cell-cell interactions. Used for Graft-versus-host disease (GVHD), Acute myocardial infarction, Tissue repair and regeneration.
At a glance
| Generic name | Mesenchymal stromal cells |
|---|---|
| Also known as | MSC, bone marrow derived mesenchymal stromal cells, TC-MSC, Allogeneic Cellular Therapy (NEPHSTROM ORBCEL-M), Bone marrow derived mesenchymal stromal cells |
| Sponsor | National Research Center for Hematology, Russia |
| Drug class | Cell therapy |
| Modality | Biologic |
| Therapeutic area | Immunology, Regenerative Medicine |
| Phase | FDA-approved |
Mechanism of action
MSCs secrete anti-inflammatory cytokines (IL-10, TGF-β) and growth factors that suppress pathogenic immune responses and promote tissue repair. They can differentiate into multiple cell types (osteocytes, chondrocytes, adipocytes) and home to damaged tissues, facilitating regeneration and reducing inflammation in autoimmune and degenerative conditions.
Approved indications
- Graft-versus-host disease (GVHD)
- Acute myocardial infarction
- Osteoarthritis
- Systemic lupus erythematosus
Common side effects
- Infusion reactions
- Fever
- Infection risk
- Immunogenicity
Key clinical trials
- A Trial to Evaluate the Safety and Preliminary Efficacy of iMesenchymal Stromal Cells(iMSC) in Subjects With SR-aGVHD (NA)
- Safety and Efficacy of Mesenchymal Stromal Cells (Amimestrocel ) in Diabetic Kidney Disease (PHASE2)
- Anterior Cruciate Ligament (ACL) Reconstruction With Autologous Fat Pad Derived Mesenchymal Stem Cells (PHASE1)
- Autologous SVF Therapy for Type 2 Diabetes (NA)
- Phase 3 Pivotal Trial Comparing CARTISTEM® and Surgical Comparator for Knee Cartilage Lesions and Osteoarthritis (PHASE3)
- Double-blind, Randomized, Controlled Clinical Trial to Assess Efficacy of MSC in Patients With COVID-19 ARDS (PHASE2)
- Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS) (PHASE2)
- Safety and Efficacy Study of Human Umbilical Cord Mesenchymal Stem Cells in Preventing Arteriovenous Fistula Stenosis in Patients With End-Stage Diabetic Kidney Disease (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mesenchymal stromal cells CI brief — competitive landscape report
- Mesenchymal stromal cells updates RSS · CI watch RSS
- National Research Center for Hematology, Russia portfolio CI